In one paragraphArticle in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
30 authors.
Yang GaoDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, Ohio.ORCID 0000-0003-1832-4380 Luis Becerra-DominguezLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-7007-9402 Charlotte Helena RivasLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-1408-7368 Robert L SatcherDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3356-4331 Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MATTHEW J ELLIS · 2014 to 2026
$24.5MVISION RESEARCH CENTERP30EY002520 · NEI · BAYLOR COLLEGE OF MEDICINE · PI Samuel M Wu · 1985 to 2026
$14.8MOsteoclast-Independent Mechanisms of Early-Stage Bone Colonization of Breast CancerR01CA183878 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2014 to 2024
$3.5MNext Generation Rat Models of ER+ Breast CancerR01CA271498 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Yi Li, Xiang Zhang · 2022 to 2026
$3.1MUnveiling the mechanisms underlying secondary metastasis and possible therapeutic windowsR01CA251950 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ZHANG, XIANG · 2020 to 2024
$2.6MModulation of Epigenetic Target in the Bone to Treat Breast Cancer MetastasisR01CA277838 · NCI · RICE UNIVERSITY · PI Han Xiao, Xiang Zhang · 2023 to 2026
$2.6MOsteogenic Niche Biology in Progression and Endocrine Resistance of Bone MetastasesR01CA221946 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ROWLEY, DAVID R · 2018 to 2022
$2.4MRewired Metabolism Regulates Vessel Normalization and ImmunosuppressionR01CA227904 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SREEKUMAR, ARUN, ZHANG, XIANG · 2019 to 2023
$2.3MHigh Throughput Genomic Sequencer at BCM Core FacilityS10OD023469 · OD · BAYLOR COLLEGE OF MEDICINE · PI CHEN, RUI · 2017 to 2017
$600kHigh Memory High-Performance Computer Cluster for Biomedical ResearchS10OD032185 · OD · BAYLOR COLLEGE OF MEDICINE · PI HILSENBECK, SUSAN G. · 2022 to 2022
$596kHarnessing neutrophils to improve the efficacy of immune checkpoint inhibitors in breast cancerR00CA279899 · NCI · OHIO STATE UNIVERSITY · PI Yang Gao · 2025 to 2026
$497kCancer Prevention and Research Institute of Texas (CPRIT) RP180672Cancer Prevention and Research Institute of Texas (CPRIT) RP200504National Cancer Institute (NCI) CA183878National Cancer Institute (NCI) CA221946National Cancer Institute (NCI) CA227904National Cancer Institute (NCI) CA251950National Cancer Institute (NCI) CA253533National Cancer Institute (NCI) P50CA186784National Institutes of Health (NIH) CA125123National Institutes of Health (NIH) P30EY002520National Institutes of Health (NIH) S10OD023469National Institutes of Health (NIH) S10OD025240National Institutes of Health (NIH) S10OD032185NCI NIH HHS K99 CA279899NCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS R00 CA279899NCI NIH HHS R01 CA183878NCI NIH HHS R01 CA221946NCI NIH HHS R01 CA227904NCI NIH HHS R01 CA251950NCI NIH HHS R01 CA271498NCI NIH HHS R01 CA277838NCRR NIH HHS S10 RR024574NEI NIH HHS P30 EY002520NIH HHS S10 OD023469NIH HHS S10 OD025240NIH HHS S10 OD032185U.S. Department of Defense (DOD) HT9425-23-1-0493
6 · The paper itselfAbstract
Neutrophils are a prominent component of the tumor microenvironment (TME) that can have both pro- and antitumor functions. By analyzing neutrophils across different human cancers, we revealed an ICAM1high subset enriched in the TME, which was also observed in murine triple-negative breast cancer (TNBC) models. ICAM1high neutrophils exhibited an enhanced capacity for cell-cell adhesion specifically with tumor cells retaining epithelial features, and this adhesion conferred mutual advantages to both cell types. In contrast, cancer cells with mesenchymal-like phenotypes were vulnerable to neutrophil-mediated cytotoxicity due to decreased cell adhesion and elastase resistance. These opposite effects drove tumor evolution toward a dichotomy of neutrophil-enriched, epithelial-like ecosystems and macrophage-enriched, mesenchymal-like ecosystems. As ICAM1high neutrophils can reverse migrate from tissue into the circulation, the adhesive and reverse migratory properties together mediate metastatic intravasation. Spatial transcriptomic and tissue microarray analyses demonstrated interactions between tumor cells, neutrophils, and endothelial cells in human TNBC, particularly in non-Hispanic Europeans compared with African American patients. Together, this study demonstrated tumor-immune coevolution in which neutrophils instruct the phenotypes and metastatic behaviors of TNBC, which may preferentially occur in patients of certain ancestries. SIGNIFICANCE: A distinct subset of ICAMhigh tumor-infiltrating neutrophils with increased adhesion and reverse transendothelial migration shapes tumor phenotypes and metastatic potential through mutually beneficial interactions with epithelial cancer cells.
Indexed as
Intercellular Adhesion Molecule-1NeutrophilsTriple Negative Breast NeoplasmsAnimalsCell AdhesionCell Line, TumorCell MovementFemaleHumansMiceNeoplasm MetastasisTumor MicroenvironmentICAM1 protein, humanIntercellular Adhesion Molecule-1
Identifiers
PMID42207963
PMCPMC13293467
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390